[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642794":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":35,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Sohag University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"MASLD patients",null,"Patients older than 18 years were diagnosed with MASLD according to Delphi consensus criteria , patients will undergo complete history , examination and the following investigations, including : CBC , lipid profile, serum creatinine , serology and abdominal ultrasound then inflammatory biomarkers will be calculated :\n\n* Neutrophil-to-Lymphocyte Ratio (NLR).\n* Platelet-to-Lymphocyte Ratio (PLR).\n* Neutrophil-to-Albumin Ratio (NPAR).\n* Systemic Immune-Inflammatory Index (SII)= (Platelet count × Neutrophil count) \u002F Lymphocyte count.\n* Systemic Inflammatory Response Index (SIRI) = (Neutrophil count × Monocyte count) \u002F Lymphocyte count.\n\nto evaluate inflammatory biomarkers in MASLD patients .",[13],{"name":14,"affiliation":15,"role":16},"Safaa Kh Abdalla, MD","Sohag University, Faculty of Medicine","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Alaa N Mohamed, MBBCh","CONTACT","01140559397","alaa_naser_post@med.sohag.edu.eg",[24],{"facility":25,"status":10,"city":26,"state":10,"zip":10,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":10},"Suhag university , faculty of medicine","Sohag","Egypt","EG",{"type":30,"coordinates":31},"Point",[32,33],31.69478,26.55695,{"lat":33,"lon":32},{"type":16,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Alaa Nasser Mohamed","Resident at tropical medicine and gastroenterology department","100642794","association-between-fatty-liver-and-inflammatory-biomarkers-100642794",false,"NCT07636915","Association Between Fatty Liver and Inflammatory Biomarkers","Association Between Systemic Inflammatory Indexes and Metabolic Dysfunction Associated Steatotic Liver Disease","MASLD","Inclusion Criteria:\n\n* Patient older than 18 years were diagnosed with MASLD according to Delphi consensus criteria (Rinella et al., 2024). Attend to outpatient clinic of Tropical Medicine Department, Sohag University\n\nExclusion Criteria:\n\n1. Significant alcohol consumption (\\>20 g\u002Fday for females, \\>30 g\u002Fday for males).\n2. Other causes of chronic liver disease:\n\n   * Viral hepatitis (HBV, HCV)\n   * Autoimmune hepatitis.\n   * Wilson's disease.\n   * Hemochromatosis.\n   * Drug-induced liver injury.\n3. Active infection or acute inflammatory conditions.\n4. Malignancy.\n5. Pregnancy.","ALL","18 Years",{"count":49,"type":50},100,"ESTIMATED","OBSERVATIONAL","The newly adapted definition for MASLD includes evidence for hepatic steatosis by imaging or biopsy with at least one of the five cardiometabolic criteria; BMI ≥ 25 kg\u002Fm2 (≥23 kg\u002Fm2 in Asian) or waist circumference \\>94 cm in men, \\>80 cm in women, fasting serum glucose ≥ 126 mg\u002FdL or 2 hour post load glucose level ≥ 140 mg\u002FdL or HbA1c ≥ 5.7% or on treatment for type 2 diabetes mellitus ,blood pressure ≥130\u002F85 mmHg or antihypertensive treatment, plasma triglycerides ≥ 150 mg\u002FdL or on lipid lowering drug, and plasma HDL cholesterol \\\u003C 40 mg\u002FdL for men and \\\u003C 50 mg\u002FdL for women or on lipid lowering drug treatment (Rinella et al., 2024).\n\nThese metabolic factors contribute to disease progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma (Eid et al., 2024).\n\nWhile multiple biological pathways contribute to MASLD pathogenesis; systemic inflammation has emerged as a pivotal mechanism linking metabolic dysfunction to liver injury (Bessone et al., 2019)",[54],"Fatty Liver",[44],"NOT_YET_RECRUITING","2026-06-08",{"date":59,"type":60},"2026-06-10","ACTUAL",{"date":62,"type":50},"2026-07-01",{"date":64,"type":50},"2027-03-01",{"name":5,"class":6},1]